
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing valacyclovir hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing valacyclovir are listed in tablet form. No finished valacyclovir product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Valacyclovir is an oral antiviral for herpes simplex and varicella-zoster infections that compounding pharmacies prepare as oral suspensions and capsules.
Valacyclovir is a prodrug of acyclovir, a deoxynucleoside analogue DNA polymerase inhibitor. After swallowing, it is almost completely converted in the gut wall and liver to acyclovir and L-valine. In infected cells, viral thymidine kinase activates acyclovir, which blocks viral DNA polymerase in herpes simplex and varicella-zoster viruses. The manufactured product is Valtrex (GlaxoSmithKline) and generic valacyclovir hydrochloride tablets. Valtrex is FDA-approved in adults for cold sores, genital herpes (first and recurrent episodes, suppression, and reduction of transmission) and herpes zoster, and in children for cold sores from age 12 and chickenpox from age 2 to under 18. No manufactured liquid exists. Prescribers may order valacyclovir compounded as an oral suspension for someone who cannot swallow tablets, as a capsule in a strength not manufactured, or in a dye-free vehicle. Compounded valacyclovir preparations are not FDA-approved and require a prescription.
The Valtrex label carries no boxed warning. Its warnings include thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in immunocompromised patients at high doses; acute kidney failure, more likely in older adults, people with kidney disease, dehydration or other kidney-toxic drugs; central nervous system effects such as agitation, hallucinations, confusion and encephalopathy; and severe skin reactions. The label states no clinically significant drug or food interactions are known. People who have had a serious allergic or skin reaction to valacyclovir or acyclovir should not take it. Decades of data have not shown a risk of major birth defects. Acyclovir reaches breast milk in small amounts; a drugs.com breastfeeding review summarizing the LactMed record calls valacyclovir a treatment of choice for herpes during breastfeeding. For headache, nausea or stomach pain, talk to your prescriber or pharmacist; seek care right away for confusion, decreased urination, swelling, fever with bruising, or a blistering rash.
Valacyclovir hydrochloride is rapidly absorbed and converted by first-pass intestinal and hepatic hydrolysis to acyclovir and L-valine, giving an absolute acyclovir bioavailability of about 54.5 percent (Valtrex label), versus 10 to 20 percent for oral acyclovir (StatPearls). Valacyclovir protein binding is 13.5 to 17.9 percent and acyclovir 9 to 33 percent; acyclovir plasma half-life averages 2.5 to 3.3 hours with normal renal function and about 4 hours during hemodialysis. Elimination is renal by glomerular filtration and tubular secretion, so dosing is reduced for renal impairment. Labeled indications (Valtrex): herpes labialis, genital herpes (initial, recurrent, suppressive and transmission reduction) and herpes zoster in adults; herpes labialis from age 12 and varicella from age 2. The label's section 2.3 describes extemporaneous valacyclovir oral suspension prepared from tablets for pediatric patients who cannot take a solid dosage form, refrigerated and discarded after 28 days, the basis on which prescribers have ordered compounded suspension. Dosing is per prescriber, adjusted to creatinine clearance. Monitoring: renal function and hydration, especially in older adults and with nephrotoxic co-medication; mental status in renal impairment; platelets and hemolysis signs in immunocompromised patients on prolonged high doses. Not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally